Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

This study has been completed.
Sponsor:
Collaborator:
Janssen, LP
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00095134
First received: November 1, 2004
Last updated: December 5, 2011
Last verified: December 2011